Evidence map›Paper›PMID 27620390›Full record

Trial reportHypertension (Dallas, Tex. : 1979)2016

Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study.

Islam Y Elgendy, Anthony A Bavry, Yan Gong, Eileen M Handberg, Rhonda M Cooper-DeHoff, Carl J Pepine

Registry-linked trialOpen access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Hypertension (Dallas, Tex. : 1979), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00133692 (INternational VErapamil SR Trandolapril STudy), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00133692 phase4completednot on this map

INternational VErapamil SR Trandolapril STudy

TypeinterventionalSponsorUniversity of FloridaRan1997 to 2003Enrolled22,000ConditionsHypertension, Coronary Artery DiseaseArmsVerapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ), Atenolol/HCTZ/Trandolapril
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Phospholipase AThe journal of venomous animals and toxins including tropical diseases · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Advancements in pharmacotherapy for angina.Expert opinion on pharmacotherapy · 2017
    Review
  14. Blood pressure control in type 2 diabetic patients.Cardiovascular diabetology · 2017
    Review
  15. Experimental and early investigational drugs for angina pectoris.Expert opinion on investigational drugs · 2016
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Islam Y ElgendyFrom the Division of Cardiovascular Medicine, College of Medicine (I.Y.E., A.A.B., R.M.C, C.J.P.) and Department of Pharmacotherapy and Translational Research, College of Pharmacy (Y.G., R.M.C.), University of Florida, Gainesville; and Medical Service, Cardiology Section, North Florida/South Georgia Veterans Health System, Gainesville (A.A.B.). islam.elgendy@medicine.ufl.edu.
Anthony A BavryFrom the Division of Cardiovascular Medicine, College of Medicine (I.Y.E., A.A.B., R.M.C, C.J.P.) and Department of Pharmacotherapy and Translational Research, College of Pharmacy (Y.G., R.M.C.), University of Florida, Gainesville; and Medical Service, Cardiology Section, North Florida/South Georgia Veterans Health System, Gainesville (A.A.B.).
Yan GongFrom the Division of Cardiovascular Medicine, College of Medicine (I.Y.E., A.A.B., R.M.C, C.J.P.) and Department of Pharmacotherapy and Translational Research, College of Pharmacy (Y.G., R.M.C.), University of Florida, Gainesville; and Medical Service, Cardiology Section, North Florida/South Georgia Veterans Health System, Gainesville (A.A.B.).
Eileen M HandbergFrom the Division of Cardiovascular Medicine, College of Medicine (I.Y.E., A.A.B., R.M.C, C.J.P.) and Department of Pharmacotherapy and Translational Research, College of Pharmacy (Y.G., R.M.C.), University of Florida, Gainesville; and Medical Service, Cardiology Section, North Florida/South Georgia Veterans Health System, Gainesville (A.A.B.).
Rhonda M Cooper-DeHoffFrom the Division of Cardiovascular Medicine, College of Medicine (I.Y.E., A.A.B., R.M.C, C.J.P.) and Department of Pharmacotherapy and Translational Research, College of Pharmacy (Y.G., R.M.C.), University of Florida, Gainesville; and Medical Service, Cardiology Section, North Florida/South Georgia Veterans Health System, Gainesville (A.A.B.).
Carl J PepineFrom the Division of Cardiovascular Medicine, College of Medicine (I.Y.E., A.A.B., R.M.C, C.J.P.) and Department of Pharmacotherapy and Translational Research, College of Pharmacy (Y.G., R.M.C.), University of Florida, Gainesville; and Medical Service, Cardiology Section, North Florida/South Georgia Veterans Health System, Gainesville (A.A.B.).
North Florida/South Georgia Veterans Health System · US

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
NCATS NIH HHS UL1 TR001427
6 · The paper itself

Abstract

The dyad of hypertension and coronary artery disease is prevalent; however, data on systolic blood pressure (SBP) control and long-term all-cause mortality are lacking. Using extended follow-up data from the US cohort of the International Verapamil (SR)/Trandolapril Study (mean 11.6 years), subjects were categorized by age at enrollment (50 to <60 and ≥60 years). Cox proportional adjusted hazard ratios (HRs) were constructed for time to all-cause mortality according to achieved mean SBP. In those 50 to <60 years and using a referent SBP of <130 mm Hg, an achieved SBP of 130 to 140 mm Hg was associated with a similar risk of mortality (HR, 1.03; 95% confidence interval [CI], 0.87-1.23), whereas an achieved SBP of ≥140 mm Hg was associated with an increased risk of mortality (HR, 1.80; 95% CI, 1.53-2.11). Among subjects aged ≥60 years and using a referent SBP of <130 mm Hg, an achieved SBP 130 to 140 mm Hg was associated with a lower mortality risk (HR, 0.92; 95% CI, 0.85-0.98). There was an increased risk of mortality with an achieved SBP ≥150 mm Hg (HR, 1.34; 95% CI, 1.23-1.45), but not with an achieved SBP 140 to 150 mm Hg (HR, 1.02; 95% CI, 0.94-1.11). In hypertensive patients with coronary artery disease, achieving a SBP of 130 to 140 mm Hg seems to be associated with lower all-cause mortality after ≈11.6 years of follow-up. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00133692.

Indexed as

AgedBlood Pressure DeterminationCause of DeathComorbidityCoronary Artery DiseaseDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansHypertensionIndolesInternationalityMaleMiddle AgedProportional Hazards ModelsIndolestrandolaprilVerapamiladultblood pressurecoronary artery diseasehypertensionmortality

Identifiers

PMID27620390
PMCPMC5063713
OpenAlexW2520992996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.